The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Exciting treatment combinations emerging in myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses current and upcoming treatment combinations in multiple myeloma, drawing focus on immunotherapies. Dr Costa first highlights the promise of CAR-T therapy, and then goes on to discuss bispecific T-cell engagers (BiTEs). Other promising approaches in this field include monoclonal antibodies, and Dr Costa highlights some clinical trials investigating the earlier use of these agents, such as the MajesTEC-1 (NCT04557098) and MagnetisMM-3 (NCT04649359) trials. To conclude, Dr Costa discusses the role of BCL2 inhibitors and their place in the myeloma treatment landscape. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Research support: Amgen, Janssen, BMS, AbbVie, Ionis, Genentech
Honorarium: Amgen, Janssen, Sanofi, Karyopharm, BMS, Astra Zeneca, Adaptive Biotechnologies, Takeda, Pfizer
